ResMed's Q4 Results: Analysts Say Uncertain Market Dynamics Follow Amid Philips Re-Entry
Portfolio Pulse from Vandana Singh
ResMed Inc (RMD) reported Q4 adjusted EPS of $1.60, missing the consensus of $1.67. Revenues increased 23% to $1.12 billion, driven by increased demand for sleep and respiratory care devices. KeyBanc reiterated the Overweight rating but lowered the price target to $260. Needham kept the Hold rating on the stock. Analysts expect that if Philips (PHG) reenters the market, ResMed's growth could slow. RMD shares are down 17.20% at $182.01.
August 04, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ResMed's Q4 earnings missed expectations, leading to a drop in its share price. The company's growth could slow if Philips reenters the market.
ResMed's Q4 earnings missed the consensus, which likely contributed to the drop in its share price. The potential reentry of Philips into the market could increase competition and slow ResMed's growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Philips' potential reentry into the market could slow ResMed's growth. The timing of this reentry is uncertain.
Philips' potential reentry into the market could increase competition for ResMed. However, the timing of this reentry is uncertain, making it difficult to predict the impact on Philips' stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60